L.E.K.’s Take on China Medtech: Optimistic Macro View, Short-Term Hit Hard Stephen Sunderland Read more
Related Practice MedTech Despite the COVID-19 lockdown, Stephen Sunderland foresees limited disruption 07102020100744
Article MedTech Hospital Priorities 2025 China Edition: Key Findings for Medtech and Pharma Companies June 20, 2025
Case Study Life Sciences & Pharma Global Manufacturing Footprint Rationalization for a Leading Biopharmaceutical Company March 31, 2025 A leading biopharmaceutical company engaged L.E.K. Consulting to optimize its global manufacturing network. The client sought to reduce costs while…
Published Articles Life Sciences & Pharma A Strategic Framework for Evaluating AI in Drug Discovery December 6, 2024
Published Articles Business Services What do leaders get wrong when making high-risk decisions? October 10, 2024
Video / Webinar Healthcare Services Global Collaboration Opportunities in China's Healthcare Innovation August 7, 2024
